Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo M Horlings

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Breast Cancer Research : BCR|December 28, 2019
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancerIris Nederlof, Davide De Bortoli, Yacine Bareche, et al.
Nature Genetics|June 7, 2011
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promotersTiffany Hung, Yulei Wang, Michael F Lin, et al.
The Lancet. Digital Health|December 11, 2025
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancerYoni Schirris, Rosie Voorthuis, Mark Opdam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2018
Correction: TERT promoter mutation in adult granulosa cell tumor of the ovaryJessica A Pilsworth, Dawn R Cochrane, Zhouchunyang Xia, et al.
Oncoimmunology|December 8, 2018
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survivalMarcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, et al.
Nature Communications|August 5, 2022
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancersTom Van Nyen, Mélanie Planque, Lilian van Wagensveld, et al.
Oncotarget|September 15, 2017
Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 studyFleur Weeber, Geert A Cirkel, Marlous Hoogstraat, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 17, 2018
TERT promoter mutation in adult granulosa cell tumor of the ovaryJessica A Pilsworth, Dawn R Cochrane, Zhouchunyang Xia, et al.
Journal of the National Cancer Institute|June 15, 2016
Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical PhenotypeMelissa K McConechy, Anniina Färkkilä, Hugo M Horlings, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Breast Cancer Research : BCR|December 28, 2019
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancerIris Nederlof, Davide De Bortoli, Yacine Bareche, et al.
Nature Genetics|June 7, 2011
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promotersTiffany Hung, Yulei Wang, Michael F Lin, et al.
The Lancet. Digital Health|December 11, 2025
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancerYoni Schirris, Rosie Voorthuis, Mark Opdam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2018
Correction: TERT promoter mutation in adult granulosa cell tumor of the ovaryJessica A Pilsworth, Dawn R Cochrane, Zhouchunyang Xia, et al.
Oncoimmunology|December 8, 2018
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survivalMarcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, et al.
Nature Communications|August 5, 2022
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancersTom Van Nyen, Mélanie Planque, Lilian van Wagensveld, et al.
Oncotarget|September 15, 2017
Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 studyFleur Weeber, Geert A Cirkel, Marlous Hoogstraat, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 17, 2018
TERT promoter mutation in adult granulosa cell tumor of the ovaryJessica A Pilsworth, Dawn R Cochrane, Zhouchunyang Xia, et al.
Journal of the National Cancer Institute|June 15, 2016
Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical PhenotypeMelissa K McConechy, Anniina Färkkilä, Hugo M Horlings, et al.
Pageof 11